Aligos Therapeutics Stock Price Prediction
| ALGS Stock | USD 16.87 0.11 0.66% |
Momentum 41
Sell Extended
Oversold | Overbought |
EPS Estimate Next Quarter (1.49) | EPS Estimate Current Year (10.36) | EPS Estimate Next Year (13.01) | Wall Street Target Price 103.3333 | EPS Estimate Current Quarter (2.16) |
Using Aligos Therapeutics hype-based prediction, you can estimate the value of Aligos Therapeutics from the perspective of Aligos Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Aligos Therapeutics using Aligos Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Aligos using crowd psychology based on the activity and movement of Aligos Therapeutics' stock price.
Aligos Therapeutics Implied Volatility | 1.51 |
Aligos Therapeutics' implied volatility exposes the market's sentiment of Aligos Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Aligos Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Aligos Therapeutics stock will not fluctuate a lot when Aligos Therapeutics' options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Aligos Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Aligos because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Aligos Therapeutics after-hype prediction price | USD 18.32 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Aligos |
Aligos Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Aligos Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Aligos Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Aligos Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Aligos Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Aligos Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Aligos Therapeutics' historical news coverage. Aligos Therapeutics' after-hype downside and upside margins for the prediction period are 10.97 and 25.67, respectively. We have considered Aligos Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Aligos Therapeutics is not too volatile at this time. Analysis and calculation of next after-hype price of Aligos Therapeutics is based on 3 months time horizon.
Aligos Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Aligos Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aligos Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Aligos Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.43 | 7.29 | 0.02 | 0.01 | 3 Events / Month | 5 Events / Month | In about 3 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
16.87 | 18.32 | 8.60 |
|
Aligos Therapeutics Hype Timeline
Aligos Therapeutics is presently traded for 16.87. The entity has historical hype elasticity of -0.02, and average elasticity to hype of competition of -0.01. Aligos is forecasted to increase in value after the next headline, with the price projected to jump to 18.32 or above. The average volatility of media hype impact on the company the price is over 100%. The price appreciation on the next news is projected to be 8.6%, whereas the daily expected return is presently at -0.43%. The volatility of related hype on Aligos Therapeutics is about 53018.18%, with the expected price after the next announcement by competition of 16.86. The company has return on total asset (ROA) of (0.6732) % which means that it has lost $0.6732 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4669) %, meaning that it created substantial loss on money invested by shareholders. Aligos Therapeutics' management efficiency ratios could be used to measure how well Aligos Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.7 in 2025. Return On Capital Employed is likely to drop to -0.83 in 2025. At this time, Aligos Therapeutics' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 14.9 M in 2025, despite the fact that Other Assets are likely to grow to (2 M). Given the investment horizon of 90 days the next forecasted press release will be in about 3 days. Check out Aligos Therapeutics Basic Forecasting Models to cross-verify your projections.Aligos Therapeutics Related Hype Analysis
Having access to credible news sources related to Aligos Therapeutics' direct competition is more important than ever and may enhance your ability to predict Aligos Therapeutics' future price movements. Getting to know how Aligos Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Aligos Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| CTMX | CytomX Therapeutics | (0.05) | 10 per month | 0.00 | (0.05) | 7.32 | (7.45) | 23.37 | |
| SPRO | Spero Therapeutics | (0.02) | 9 per month | 0.00 | (0.14) | 4.85 | (6.25) | 21.98 | |
| NLTX | Neoleukin Therapeutics | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| TIL | Instil Bio | 0.39 | 5 per month | 0.00 | (0.01) | 14.84 | (9.39) | 33.50 | |
| NXTC | NextCure | (0.03) | 6 per month | 0.00 | (0.16) | 6.49 | (7.23) | 18.86 | |
| ASMB | Assembly Biosciences | (0.32) | 8 per month | 0.00 | (0.02) | 7.86 | (5.39) | 24.82 | |
| ACHL | Achilles Therapeutics PLC | (0.02) | 4 per month | 0.97 | 0.13 | 2.59 | (2.80) | 22.15 | |
| NUVB | Nuvation Bio | (0.06) | 7 per month | 0.00 | (0.1) | 5.62 | (7.12) | 23.46 |
Aligos Therapeutics Additional Predictive Modules
Most predictive techniques to examine Aligos price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Aligos using various technical indicators. When you analyze Aligos charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Aligos Therapeutics Predictive Indicators
The successful prediction of Aligos Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Aligos Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Aligos Therapeutics based on analysis of Aligos Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Aligos Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Aligos Therapeutics's related companies. | 2022 | 2023 | 2024 | 2025 (projected) | Current Ratio | 4.03 | 5.9 | 6.79 | 8.15 | Net Debt To EBITDA | 0.73 | 1.46 | 1.32 | 1.0 |
Story Coverage note for Aligos Therapeutics
The number of cover stories for Aligos Therapeutics depends on current market conditions and Aligos Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Aligos Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Aligos Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Aligos Therapeutics Short Properties
Aligos Therapeutics' future price predictability will typically decrease when Aligos Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Aligos Therapeutics often depends not only on the future outlook of the potential Aligos Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Aligos Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 24.9 M | |
| Cash And Short Term Investments | 135.7 M |
Additional Tools for Aligos Stock Analysis
When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.